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Allergic rhinitis (AR) and asthma are considered as manifestations of a common 
inflammatory process rather than separate diseases. In our earlier study, AR was under-
diagnosed and under-treated in children with asthma, and when present, AR was associated 
with severe asthma. The aim of the present study was to evaluate if concomitant AR has an 
influence on lung function in school-aged children with asthma.  Data on AR and lung 
function, measured by flow-volume spirometry (FVS), were retrospectively collected from 
hospital records of 252 school-aged children with doctor-diagnosed asthma. The limits of 
abnormal airflow values were 80% of predicted for FEV1, 88% for FEV% (FEV 1/FCV) and 
62% of predicted for FEF50.   At least one parameter in FVS was abnormal in 50.4 % of the 
study subjects.  There were no statistically significant differences between any lung function 
parameter and the AR status or the medication used for AR. The result was similar 
regardless of whether FVS parameters were analyzed as dichotomized or continuous 
variables. The present retrospective hospital chart review was not able to reveal any 
significant associations between the presence, treatment or severity of AR and lung function 
in school-aged children with asthma.  
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Allergic rhinitis (AR) and asthma are considered as 
manifestations of a common inflammatory process rather 
than separate diseases [1]. The prevalence of AR among 
school-aged children with asthma is approximately 75%, 
and conversely, asthma has been diagnosed in 10-40% of 
patients with AR [2].  Studies in both adults and children 
have shown that AR may be associated with bronchial 
hyper-reactivity (BHR) [3-5].  In a recent study, BHR was 
documented in 33.2% of the children who had AR but not 
asthma [5]. In both adults and children, AR is a 
significant risk factor for emerging asthma [1], and AR 
may deteriorate asthma balance and increase asthma 
severity [6-10]. 
 
Measurement of lung function by flow-volume 
spirometry (FVS) is an objective way to demonstrate 
bronchial obstruction, to estimate asthma severity and to 
monitor asthma balance and asthma therapy in patients 
aged >5 years [11]. Despite this, no studies have been 
published on the influence of allergic rhinitis to lung 
function in children with asthma. 
 
In our recent study, AR was both under-diagnosed and 
under-treated in school-aged children with doctor-
diagnosed asthma, and those with AR presented with 
more severe asthma requiring inhaled steroids combined 
with long-acting beta-agonists more often than asthma 
patients with no AR [12]. The aim of the present study 
was to evaluate the association between AR and lung
function in the same group of school-aged children with 
doctor-asthma. 
 
Material and Methods 
This paper belongs to our retrospective study serie on 
allergic rhinitis (AR) in school-aged patients with doctor-
diagnosed asthma [12]. In brief, 903 children aged 7-15 
years attended at least one regular control visit for asthma 
in the Department of Pediatrics, Tampere University 
Hospital, during the year 2002. The hospital provides  
secondary-level care for a population of about 90,00  
children. All Children had asthma diagnosis J45* 
according to the international classification of diseases 
(ICD-10). A random sample of 400 children with 
proportional allocation by age and gender was taken from 
the eligible children. After checking of hospital records, 
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28 children were excluded since they did not fulfill the 
inclusion criteria (doctor-diagnosed asthma, regular 
control visit) and so, the study group consisted of 372 
children with asthma. The presence or absence of AR was 
actively recorded in hospital cards for 266(71.5%) 
children. As published earlier [12], AR diagnosis was 
considered if the doctors had recorded the diagnostic code 
4779A (ICD-9), or J30* (ICD-10), or the diagnosis 
“allergic rhinitis”, or the synonyms “seasonal rhinitis” or 
“hay fever”. If the AR diagnosis was not recorded but 
nasal symptoms suggestive for AR were recorded, such as 
runny nose, stuffy nose, itching or sneezing during pollen 
seasons or animal contacts, the children were considered 
to have AR symptoms only. 
 
Data on lung function measured by flow-volume 
spirometry (FVS) were collected for the period of 12
months before or after the control visit for asthma in 
2002. Adequate lung function data were available in 
252(94.7%) of the 266 children, and these asthma patients 
(154 boys and 98 girls) form the subjects of the prsent 
study. Their basic data, including asthma and AR 
treatments, are presented in Table 1. In our hospital, lung 
function tests are not performed during acute respiatory 
symptoms, whether caused by infection or allergy. 
 
FVS was studied by VMAX 20c 4.0 (SensorMedics, 
Milwaukee, Wisconsin, USA). At least two graphically 
cceptable curves had to be present, and the curve with the 
highest sum of forced expiratory volume in 1 second 
(FEV1) and forced vital capacity (FVC) was chosen to the 
analyses. Lung function parameters were expressed both 
as absolute values and as percentages of the gender-
specific and height-related reference values (% of 
predicted) for Finnish children [13]. The parameters 
registered were FVC, FEV1, peak expiratory flow (PEF) 
and forced expiratory flow at 50% of vital capacity 
(FEF50).  FEV% was calculated from FEV1 and FVC 
using the following formula: FEV1 / FVC x 100. The 
limits of abnormal airflow values were 80% of predicted 
for FEV1, 88% for FEV% and 62% of predicted for FEF50 
[14]. If one or more of these three parameters were b low 
these limits, the child was defined to have reduced lung 
function.  
 
Since only hospital charts were retrieved and data 
registered during routine control visits were used, with no 
new contact with the subjects, the study was performed 
by the permission of the Chief Doctor of the Tampere 
University Hospital. 
 
Statistical analyses were carried out by SPSS Statistics 
17.0 software (SPSS Inc, Chicago, Illinois, USA). The 
results by categorized variables are expressed as 
frequencies and percentages, and the significances of the 
differences between the groups were tested by Pearson`s 
Chi-square and Fischer´s exact tests. The results by 
quantitative variables are expressed mainly as medians 
and ranges. The significances of the differences between 
the groups were tested by Kruskal-Wallis and Mann-
Whitney tests. When FVS parameters were analyzed in 
relation to the presence of AR and asthma severity, the 
differences were tested with one-way analysis of variance. 
Logistic regression adjusted for asthma treatment was 
used to analyze the association between the AR status 





In all, 127(50.4%) asthma patients had reduced lung 
function that is an abnormal value in FEV1 of predicted, 
FEV% or FEF50 of predicted. FEV% revealed 97.6%, 
FEV1 8.7% and FEF50 13.4% of the reduced lung function 
cases. There were no statistically significant differences in 
lung function between the three groups based on AR 
diagnosis and symptoms (Table 2).  
 
Table 1. Clinical profile of the study group 
 
  N % 
 
Gender   
 Boy 154 61.1 
 Girl 98 38.9 
Allergic rhinitis   
 Diagnosis 82 32.5 
 Symptoms only 146 57.9 
 No 24 9.5 
Asthma treatment   
 Steroids combined with long-acting 
beta-agonists 
65 25.8 
 Steroids only 131 52.0 
 No steroids 56 22.2 
Treatment for allergic rhinitis*   
 Nasal steroids only 24 10.5 
 Antihistamines only 63 27.6 
 Nasal steroids and antihistamines 54 23.7 
 No treatment 87 38.2 
*Data available in 228 cases 
 
The severity of asthma, assessed by required mainten c  
medication, had no association with reduced FEV% or 
FEF50 of predicted (Data not shown). FEV1 was abnormal 
in 9.2% of the patients treated with inhaled steroids com-
bined with long-acting beta agonists, compared with1.5% 
and 5.4% in the other two groups (p=0.028).  
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Table 2. Reduced lung function in relation to allergic 
rhinitis  
 










Reduced lung function^ 44 
(53.7 
%) 
70 (47.9 %) 13 (54.2 %) 0.658 
FEV1  < 80* 6 (7.3 
%) 
3 (2.1 %) 2 (8.3 %) 0.066 
FEV % < 88 42 
(51.2 
%) 
69 (47.3 %) 13 (54.2 %) 0.744 
FEF50  < 62* 6 (7.3 
%) 
7 (4.8 %) 4 (16.7 %) 0.096 
* % of predicted 
^FEV1 < 80 or FEV% < 88 or FEF50 < 62 
 
Table 3. Lung function in relation to allergic rhinitis  
 
 Median (range) Allergic rhinitis  
Parameter  P-value 
 Diagnosis Symptoms 
only 
No  
 (N=82) (N=146) (N=24)  
FEV1*  98.0 (62-129) 97.0 (71-130) 97.0 (68-122) 0.586 
FEV % 87.0 (63-100) 88.0 (53-100) 87.0 (71-110) 0.735 
FEF50*  89.5 (51-182) 91.5 (51-187) 82.0 (51-174) 0.308 
FVC*  99.0 (76-133) 101.0 (74-128) 98.0 (72-124) 0.547 
PEF*  108.0 (77-
179) 
112.0 (77-170) 108.5 (85-145) 0.286 
* % of predicted 
 
Table 4. Logistic regression: Reduced lung function in 
relation to the diagnosis of allergic rhinitis adjusted 
for asthma treatment 
 
 Allergic rhinitis 






Reduced lung function^ 44 (53.7 %) 70 (47.9 %) 13 (54.2 %) 
Odds ratio (95% CI)* 0.96 (0.38-2.41) 0.77 (0.32-1.83) 1.00 
    
FEV1 < 80 6 (7.3 %) 3 (2.1 %) 2 (8.3 %) 
Odds ratio (95% CI)* 0.59 (0.10-3.43) 0.18 (0.03-1.20) 1.00 
    
FEV% < 88 42 (51.2 %) 69 (47.3 %) 13 (54.2 %) 
Odds ratio (95% CI)* 0.87 (0.35-2.19) 0.75 (0.31-1.79) 1.00 
    
FEF50 < 62 6 (7.3 %) 7 (4.8 %) 4 (16.7 %) 
Odds ratio (95% CI)* 0.28 (0.07-1.16) 0.20 (0.05-0.79) 1.00 
^FEV1 < 80 or FEV% < 88 or FEF50 < 62 
*Vs. the group of no allergic rhinitis 
 
When the lung function parameters were analyzed as 
continuous variables, the main result of the study 
remained negative (Table 3). None of the individual 
parameters had a significant association with the 
presence of AR diagnosis or AR symptoms (Data not 
shown). Again, FEV1 of predicted was significantly 
lower in the group treated with inhaled steroids 
combined with long-acting beta agonists (median 
94.7%, range 62-129) than in the two other groups 
(median 99.1% and 97.3%, respectively) (p=0.046). 
Data on the use of AR treatment were available in 228 
cases, and the medication had no significant 
association with lung function results (Data not 
shown).  
 
All analyses were repeated separately in boys and 
girls, and the results remained as negative (Data no  
shown). Likewise, the results remained as negative 
when the association between AR and reduced lung 
function was analyzed by logistic regression adjusted 
for asthma treatment (Table 4). 
 
Among the original 372 children, lung function data 
were available in 94 cases with no AR data available. 
When these 94 children were compared with the 252 
children of the present study, there were no significant 
differences in age, gender or reduced lung function 
between the groups. Instead, the groups differed for 
asthma maintenance medication; the included children 
with data on allergic rhinitis available used more ften 
inhaled steroids combined with long-acting beta-
agonists (25.8% vs. 12.8%) and were less often 




The main result of the present study was that the 
presence or severity of AR had no significant 
association with lung function measured by FVS in 
school-aged children with asthma. The result was 
similar in the analyses by continuous and categorized 
FVS parameters. An alarming result was that over half 
of the patients had reduced lung function, though only
<10% of the findings were based on reduced FEV1. 
However, post-bronchodilator values eliminating 
temporarily reduced results were not available. As 
expected, the severity of asthma, when assessed by the 
requirement of inhaled steroids with or without long-
acting beta-agonists as maintenance medication, had 
some association with reduced FEV1 in FVS. The 
main result remained negative when analyses were 
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The present study is the first one on the associatin 
between lung function and AR in children with asthma. In 
two retrospective American studies including 2031 and 
488 adults with asthma, AR was reported by >70% of the 
participants [15]. Against expectations, patients with AR 
had better baseline lung function than those without AR, 
when measured by PEF [15]. In a small prospective cross-
sectional study, 20 adults with asthma were classified nto 
2 groups: 12 with AR and 8 without AR. Asthma patients 
without AR had more severe airflow obstruction when 
measured by FEV% [16]. The presence of an associatin 
between AR and less severe airflow obstruction may be 
understandable, if patients with asthma and concomitant 
AR have more seasonal and less non-seasonal permanent 
symptoms. Most children with asthma have seasonal 
symptoms, and although concomitant AR increases BHR 
and worsens asthma balance, AR does not necessarily 
reduce lung function, as seen also in the present study. 
 
There are only two pediatric studies on the associati n 
between AR and lung function. FEF25-75 was reduced in 
20-30%, but FEV1 or FEV% only in <10% of  children 
with AR [17, 18].  Lung function was studied in 50 
children with allergic rhinitis and house dust mite 
sensitization, and 11(22%) had reduced FEF25-75, but only 
one (2%) had reduced FEV1 [17]. During a 3-month 
treatment by nasal steroids, FEF25-75 increased to normal 
in two-thirds of the cases. In a more recent study in 200 
children with AR, 31% had reduced FEF25-75, and 11% 
had both reduced FEF25-75 and reduced FEV1 [18]. Long 
AR duration and sensitization to house dust mites 
increased the risk of lung function reduction. Both 
findings are understandable, since sensitization to house 
dust mites is rare in young children and when present, it is 
associated with permanent symptoms.  Over 250 children 
with asthma were included in the present study, and there 
were no significant associations between the presence of 
AR or required treatment for AR and lung function by 
FVS.  Due to the retrospective design of the study, the 
negative results should be interpreted with caution, and 
analyses based on allergen-specific sensitization or the 
duration of AR, for example were not possible. 
 
Studies both in adults [3, 4, 19] and in children [5, 20] 
have shown that AR may be associated with BHR even in 
the absence of asthma. In addition, an introduction of 
nasal steroids has improved BHR to metacholine [12] and 
to exercise [22] in patients with AR, and use of 
antihistamines has improved BHR in children with AR 
and asthma [23]. In line, treatment of AR with intranasal 
corticosteroids in 25 asthmatic adolescents aged 12-17 
years reduced BHR to exercise and tended to improve 
quality of life [24]. One-hundred adults with seasonal AR 
with no asthma were examined during and outside pollen 
seasons [25]. FEF25-75 was decreased in 17% during and in 
11% outside the season. FEV1 was decreased in 5% 
during the pollen season, and metacholine inhalation 
challenge was pathological in 54% both during and 
outside the pollen season [25]. The newest study included 
190 children with AR and with no asthma [5]. FEV1 was 
normal (>80% of predicted) in all included cases. 
Eighteen (9.5%) children had marked and 45(23.7%) had 
mild BHR in methacholine inhalation challenge [5]. Thus, 
BHR seems to be associated with long AR duration and 
sensitization to seasonal pollens [22, 25]. In the pr sent 
study, bronchial reactivity was not systemically studied 
and therefore not included in the analyses. 
 
In both adults and children, AR is a significant risk factor 
for the later emergence of asthma [1, 26, 27], and there is 
indirect evidence that insufficiently treated AR may 
deteriorate asthma balance [6-10]. In the German birth 
cohort study, allergic rhinitis at 5 years of age pr dicted  
developing wheezing between 5 and 13 years of age, with 
an adjusted relative risk of 3.8 [27].  In the Danish birth 
cohort, 7-year-old children with allergic and non-allergic 
rhinitis had both a 4-fold asthma risk [28]. In the present 
group of school-aged children with doctor-diagnosed 
asthma, AR was both under-diagnosed and under-treated, 
and children with AR diagnosis or AR symptoms had 
more severe asthma when assessed by the needed 
maintenance medication [12]. Though AR increased the 
severity of asthma, we were not able to confirm any 
association between reduced lung function and presenc  
AR. 
 
The present study was a retrospective retrieve of hospital 
records. There are two obvious strengths in the study.  
First, the study group was a random sample from a large 
group of over 900 eligible children, and data on lug 
function were present in over 90% of the included 
children. However, only baseline FVS results were 
available. Lung function was measured during the 
maintenance medication, but post-bronchodilation FVS 
values which reflect permanent changes in lung functio , 
were not available. Second, the sample of 252 children 
with complete data on allergic rhinitis and lung function 
available was large enough to minimize statistical errors 
allowing e.g. adjusted analyses.  An obvious shortcoming 
of the study was that the data on the presence or absence 
of allergic rhinitis were not recorded in a fourth of the 
eligible cases. When these drop-outs were compared with 
included children, the groups did not differ for age, 
gender or lung function results.  The included children 
used more often inhaled steroids with long-acting beta-
agonists which means that severe cases were over-
represented in the study cohort. This suggest that t e 
negative result of the study was not due to mild asthma 
cases, and when the main analyses were repeated as 
adjusted for asthma treatment, the results did not change.  
 
In conclusion, we were not able to confirm any signif cant 
associations between the presence or treatment of allergic 
rhinitis and lung function in school-aged children with 
asthma. Our study is the first one published on that
specific problem. Due to the retrospective design, the 
Association between allergic rhinitis and lung function in school children with asthma.  
 
Curr Pediatr Res 2013 Volume 17 Issue 1                                                                                                                           25 
results are only preliminary and should be interpreted 
with caution, and prospective studies are needed to solve 
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